Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1-Reference-Cited by-同舟云学术

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gartland Margaret¹^ORCID,Cahn Pedro²,DeJesus Edwin³,Diaz Ricardo Sobhie⁴^ORCID,Grossberg Robert⁵,Kozal Michael⁶,Kumar Princy⁷,Molina Jean-Michel⁸,Mendo Urbina Fernando⁹,Wang Marcia¹⁰,Du Fangfang¹⁰,Chabria Shiven¹¹,Clark Andrew¹²,Garside Louise¹³,Krystal Mark¹¹^ORCID,Mannino Frank¹⁰,Pierce Amy¹,Ackerman Peter¹¹,Lataillade Max¹¹

Affiliation:

1. ViiV Healthcare, Research Triangle Park, North Carolina, USA

2. Fundación Huesped, Buenos Aires, Argentina

3. Orlando Immunology Center, Orlando, Florida, USA

4. Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil

5. Montefiore Medical Center, Bronx, New York, USA

6. Department of Internal Medicine, Infectious Diseases Section, Yale University School of Medicine, New Haven, Connecticut, USA

7. Department of Medicine and Microbiology, Georgetown University Medical Center, Washington, DC, USA

8. University of Paris, Saint-Louis and Lariboisière Hospitals, Assistance Publique Hôpitaux de Paris, Paris, France

9. Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

10. GlaxoSmithKline, Collegeville, Pennsylvania, USA

11. ViiV Healthcare, Branford, Connecticut, USA

12. ViiV Healthcare, Brentford, United Kingdom

13. GlaxoSmithKline, Brentford, United Kingdom

Abstract

In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA <40 copies/mL was achieved in 163/272 (60%) Randomized Cohort (RC) participants (with 1 or 2 remaining approved fully active antiretrovirals) and 37/99 (37%) Non-randomized Cohort (NRC) participants (with 0 fully active antiretrovirals).

Funder

ViiV Healthcare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01751-21

Reference36 articles.

1. HIV MDR is still a relevant issue despite its dramatic drop over the years

2. HIV Drug Resistance — An Emerging Threat to Epidemic Control

3. Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: A systematic review

4. Identifying heavily treatment-experienced patients in a large administrative claims database;Henegar C;Abstr 10th IAS Conference on HIV Science, Abstr MOPEB236,2019

5. Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort. Abstr 10th IAS Conference on HIV Science;Pelchen-Matthews A;Abstr TUPEB222,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate;Antiviral Research;2024-09

2. Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study;HIV Medicine;2024-08-25

3. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab;Antiviral Research;2024-08

4. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

5. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir;BMC Infectious Diseases;2024-02-23